Cytotoxic T-lymphocyte responses to canarypox vector-based HIV vaccines in HIV-seronegative individuals: A meta-analysis of published studies

HIV Clinical Trials

Volumn 5, Issue 5, 2004, Pages 259-268

  Edupuganti, Srilatha ^a   Weber, David ^a,b   Poole, Charles ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

Author keywords

ALVAC HIV vaccines; Cytotoxic T cell responses; Meta analysis

Indexed keywords

CD8 ANTIGEN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT PROTEIN; VIRUS VECTOR;

ANTIBODY RESPONSE; ARTICLE; CANARYPOX VIRUS; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG RESEARCH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; META ANALYSIS; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SERODIAGNOSIS; VIRAL GENE DELIVERY SYSTEM; VOLUNTEER;

AIDS VACCINES; CANARYPOX VIRUS; CYTOTOXICITY, IMMUNOLOGIC; DOUBLE-BLIND METHOD; HIV INFECTIONS; HIV-1; HUMANS; RANDOMIZED CONTROLLED TRIALS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 9144224897     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/W9J3-0PTB-FX1V-Y3FX     Document Type: Article

References (32)

1. Letvin NL. Strategies for an HIV vaccine. J Clin Invest. 2002;110(1):15-20.
2. Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma viral load of viral RNA. Science. 1998;279:2103-2106.
3. Musey L, Hughes J, Schacker T, et al. Cytotoxic T-cell responses, viral load, and disease progression in early Human Immunodeficiency Virus type 1 infection. N Engl J Med. 1997;337:1267-1274.
4. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary Human Immunodeficiency Virus type 1 syndrome. J Virol. 1994;68:4650-4655.
5. Klein MR, van Baalen CA. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long term asymptomatics. J Exp Med. 1995;181:1356-1372.
6. Rowland-Jones SL, Dong T, Fowke KR, et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest. 1998;102:1758-1765.
7. Barouch DH, Craiu A, Kuroda MJ, et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus vaccines by IL-2/Ig plasmid administration to rhesus monkeys. Proc Natl Acad Sci USA. 2000;97:4192-4197.
8. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 2001;292(5514):69-74.
9. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits anti-immunodeficiency-virus immunity. Nature. 2202;415(6869):331-335.
10. Franchini G, Robert-Guroff M, Tartaglia J, et al. Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant vaccines, induce long-lasting protection in rhesus macaques. AIDS Res Human Retroviruses. 1995;11(8):909-920.
11. Gilbert PB, Chiu TL, Allen M, et al. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored phase I and II clinical trials. Vaccine. 2003;21:2933-2947.
12. Cohen J. Disappointing data scuttle plans for large-scale AIDS vaccine trial. Science. 2002;295(5560):1616.
13. McMichael A, Rowland-Jones SL. Cellular immune responses to HIV. Nature. 2001;410:980-987.
14. Johnston MI, Flores J. Progress in HIV vaccine development. Curr Opinion Pharmacol. 2001;1:504-510.
15. Egan MA, Pavlat WA, Tartaglia J, et al. Induction of Human Immunodeficiency Virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range restricted canarypox vector (ALVAC) carrying the HIV-1 MN env gene. J Infect Dis. 1995;171:1623-1627.
16. Belshe RB, Gorse GJ, Mulligan MJ, et al. Induction of immune responses to HIV-1 canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS. 1998;12:2407-2415.
17. Clements-Mann ML, Weinhold K, Matthews TJ, et al. Immune responses to Human Immunodeficiency Virus (HIV) type 1 induced by canarypox expressing HIV-1 MN gp120, HIV-1 SF2 recombinant gp120, or both vaccines in seronegative adults. J Infect Dis. 1998;177:1230-1246.
18. + cytotoxic t lymphocyte responses in seronegative volunteers. J Infect Dis. 1999;180:290-298.
19. AIDS Vaccine Evaluation Group 022 Protocol Team. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 env, gag, and pro in combination with rgp120. J Infect Dis. 2001;183:563-570.
20. Belshe RB, Stevens C, Gorse GJ, et al. Safety and immunogenicity of a carnarypox-vectored Human Immunodeficiency Virus type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis. 2001;183:1343-1352.
21. Gupta K, Hudgens M, Corey L, et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1 uninfected adults: AIDS vaccine evaluation group protocol 022A. J Acquir Immune Defic Syndr. 2002;29:254-261.
22. Cao H, Kaleebu P, Hom D, et al. Immunogenecity of a recombinant Human Immunodeficiency Virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV network for prevention trials 007 vaccine study. J Infect Dis. 2003;187:887-895.
23. Fleury B, Janvier G, Pialoux G, et al. Memory cytotoxic T lymphocyte responses in Human Immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp-160 of HIV-1 and boosted with a recombinant gp160. J Infect Dis. 1996;174:734-738.
24. Salmon-Ceron D, Excler JL, Finkielsztein L, et al. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-v3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AIDS Res Human Retroviruses. 1999;15(7):633-645.
25. + T cell immunogenecity of high dose live recombinant canarypox ALVAC-HIV vaccine (vCP1452) in healthy, HIV-1 uninfected adults. Presented at: 10th Conference on Retroviruses and Opportunistic Infections; 2003; Boston.
26. de Souza M, Karnasuta C, Cox J, et al. Cytotoxic T lymphocyte responses in participants enrolled in a phase I/II canarypox (ALVAC)/gp120 B/E prime-boost HIV vaccine trial in Thailand. In: Program and abstracts of the International Conference on AIDS; July 7-12, 2002. Abstract LbOr14.
27. Sterne JAC, Egger M, Smith GD. Investigating and dealing with publication and other biases. In: Egger M, Smith DG, Altman DG, eds. Systematic Reviews in Health Care: Meta-analysis in Context, 2nd ed. London: BMJ Publishing Group; 2001:189-208.
28. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med. 1999;18:2693-2708.
29. Graham BS, Wright PF. Candidate AIDS vaccines. N Engl J Med. 1995;333(20):1331-1339.
30. Gorse G, Patel G, Belshe RB. HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers. AIDS Res Human Retroviruses. 2001;17(12):1175-1189.
31. Russell ND, Michael GH, Ha R, et al. Moving to Human Immunodeficiency Virus type I vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J Infect Dis. 2003;187:226-242.
32. Hudgens MG. Estimating cumulative probabilities from incomplete longitudinal binary responses with application to HIV vaccine trials. Stat Med. 2003;22:463-479.